Rest Of Europe Patient Derived Xenografts/PDX Models Market (2025-2030)
The Rest Of Europe Patient Derived Xenografts/PDX Models Market was valued at $17.5 Million in 2025 and projected to reach to $24.5 Million by 2030, representing a compound annual growth rate of 7.0%. Rest Of Europe's PDX Models market is positioned for steady growth driven by the region's increasing emphasis on precision oncology and personalized treatment approaches.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe Patient Derived Xenografts/PDX Models Market Trends and Insights
- Rest Of Europe's PDX market is driven by increasing adoption of personalized medicine approaches and growing investment in oncology research across the region.
- The 7.0% compound annual growth rate reflects Rest Of Europe's commitment to advancing preclinical drug development platforms and improving cancer treatment outcomes through patient-derived tumor models. Rest Of Europe's PDX market benefits from a robust pharmaceutical and biotechnology sector, coupled with supportive regulatory frameworks for innovative research methodologies.
- The region's academic institutions and contract research organizations are increasingly leveraging PDX models to accelerate drug discovery timelines and reduce late-stage clinical trial failures.
- Between 2025 and 2030, Rest Of Europe is expected to see enhanced collaboration between research centers and pharmaceutical companies, further strengthening the market's expansion trajectory..
Key Market Statistics
- CAGR (2025-2030) 7.0% CAGR
- Market Size, 2025 ~USD 17.5 Million
- Forecast, 2030 ~USD 24.5 Million
- Country Rest Of Europe
Rest Of Europe Patient Derived Xenografts/PDX Models Market Overview
Market Valuation :
Rest Of Europe's PDX Models market is valued at $17.5 million in 2025, with a projected expansion to $24.5 million by 2030, representing a steady 7% CAGR.
Personalized Medicine Adoption :
Increasing adoption of personalized medicine approaches across Rest Of Europe is driving demand for PDX models, enabling tailored cancer treatment strategies and improved patient outcomes.
Oncology Research Investment :
Growing investment in oncology research infrastructure across Rest Of European countries is accelerating PDX model utilization for drug development and preclinical testing.
Growth Trajectory :
Rest Of Europe's 7% CAGR demonstrates moderate but consistent market expansion, lagging behind the global 12.5% CAGR, indicating untapped growth potential in the region.
Rest Of Europe Patient Derived Xenografts/PDX Models Market Dynamics
- The market's 7% CAGR reflects growing adoption among research institutions and pharmaceutical companies seeking advanced preclinical models for drug efficacy testing.
- Expanding healthcare budgets and collaborative research initiatives across Rest Of European nations are expected to support market expansion through 2030. The region's pharmaceutical and biotechnology sectors are increasingly recognizing PDX models as essential tools for reducing drug development timelines and improving clinical trial success rates.
- Government support for cancer research programs and partnerships between academic institutions and industry players will further accelerate market penetration.
- However, standardization of PDX protocols and cost optimization remain key challenges that stakeholders must address to unlock the region's full market potential..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Rest Of Europe's PDX market is valued at $17.5 million in 2025 and will grow to $24.5 million by 2030, representing a 7.0% CAGR.
- Rest Of Europe is witnessing increased adoption of patient-derived xenograft models in oncology research and personalized medicine development.
- Rest Of Europe's pharmaceutical and biotechnology sectors are driving demand for PDX models to improve drug efficacy and reduce clinical trial failures.
- Rest Of Europe's academic and contract research organizations are expanding PDX capabilities to support precision oncology initiatives through 2030.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Rest Of Europe Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
Target Audience
- Pharmaceutical Companies : Rest Of European pharma firms need PDX market data to evaluate preclinical testing capabilities, optimize drug development pipelines, and assess regional market expansion opportunities.
- Biotechnology Firms : Biotech companies require Rest Of Europe-specific PDX insights to identify partnership opportunities, benchmark against regional competitors, and plan market entry strategies.
- Research Institutions : Academic and research centers across Rest Of Europe need market intelligence to justify PDX model investments, secure funding, and align research capabilities with industry demand.
- Healthcare Investors : Investment firms and venture capitalists require Rest Of Europe PDX market data to identify high-growth opportunities, evaluate portfolio companies, and assess regional healthcare innovation trends.
- Medical Device/Service Providers : Companies offering PDX-related services and technologies need Rest Of Europe market analysis to understand demand drivers, pricing dynamics, and customer acquisition strategies in the region.
Key Companies in the Rest Of Europe Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Regional Market Sizing : Obtain precise market valuation data specific to Rest Of Europe, including 2025 baseline ($17.5M) and 2030 forecasts ($24.5M), enabling accurate budget allocation and investment planning.
- Growth Opportunity Assessment : Understand Rest Of Europe's 7% CAGR trajectory relative to global 12.5% growth, identifying expansion opportunities and competitive positioning within the region's emerging PDX market.
- Regional Adoption Insights : Gain intelligence on personalized medicine adoption rates and oncology research investment patterns specific to Rest Of European countries, informing market entry and expansion strategies.
- Competitive Landscape Analysis : Access Rest Of Europe-specific competitive dynamics, regulatory environment, and key market players to develop targeted go-to-market strategies and partnership opportunities.
- Strategic Decision Support : Leverage region-specific market intelligence to support investment decisions, product development priorities, and resource allocation for pharmaceutical and biotech companies operating in Rest Of Europe.
Frequently asked questions
What is the current market size of PDX models in Rest Of Europe?
Rest Of Europe's Patient Derived Xenografts/PDX Models Market is valued at $17.5 million in 2025.
What is the projected market size for PDX models in Rest Of Europe by 2030?
Rest Of Europe's PDX market is forecast to reach $24.5 million by 2030, growing at a 7.0% CAGR.
What factors are driving PDX market growth in Rest Of Europe?
Rest Of Europe's PDX market growth is driven by increased adoption of personalized medicine, growing oncology research investments, and the need to reduce clinical trial failures through improved preclinical models.
Which sectors are the primary users of PDX models in Rest Of Europe?
Rest Of Europe's pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations are the primary users of PDX models for drug development and oncology research.
How does Rest Of Europe's PDX market growth compare to global trends?
Rest Of Europe's 7.0% CAGR is more conservative than the global 12.5% CAGR, reflecting the region's steady but measured adoption of PDX technologies in research and development.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report